Press release
Pulmonary Arterial Hypertension Market Size, Share, Industry, Forecast and outlook (2024-2031)
DataM Intelligence
Global Pulmonary Arterial Hypertension Market Surpasses USD 7 Billion in 2022, Projected to Reach USD 10.6 Billion by 2030
The Pulmonary Arterial Hypertension (PAH) market has exhibited robust growth, with the global market size reaching USD 7 billion in 2022 and anticipated to achieve a value of USD 10.6 billion by 2030. This growth is marked by a steady Compound Annual Growth Rate (CAGR) of 5.3% over the forecast period from 2024 to 2031.
PAH, a subtype of pulmonary hypertension characterized by elevated blood pressure in the lungs, stems from obstructions in the tiny arteries of the lung. Although more prevalent in women aged 30-60, PAH falls under Group 1 classification with no known cure. However, available therapies aim to alleviate symptoms and enhance the quality of life for patients. Annually, 500-1000 new cases of PAH are diagnosed in the United States.
Scope of the Pulmonary Arterial Hypertension Market:
Metrics
CAGR: 5.3%
Size Available for Years: 2021-2030
Forecast Period: 2024-2031
Segments Covered:
By Drug Class
By Route of Administration
By Distribution Channel
Regions Covered: North America, Europe, Asia-Pacific, South Americ, Middle East & Africa
Fastest Growing Region: Asia-Pacific
Largest Region: North America
Report Insights Covered
Competitive Landscape Analysis
Company Profile Analysis
Market Size, Share, Growth
Demand, Recent Developments
Mergers and Acquisitions
New Product Launches
Growth Strategies
Revenue Analysis
Porter's Analysis
Pricing Analysis
Regulatory Analysis
Supply-Chain Analysis
Other Key Insights
To know more Insights Download Sample : https://www.datamintelligence.com/download-sample/pulmonary-arterial-hypertension-market
Pulmonary Arterial Hypertension Market Dynamics:
Increase in Prevalence of Pulmonary Artery Hypertension
The market is driven by the escalating prevalence of pulmonary artery hypertension. According to a recent study, the overall incidence of pulmonary arterial hypertension was 14 cases per million, surpassing the Reveal registry. This prevalence remains elevated, even when comparing the annual period prevalence and clinic cohort limited to patients with hemodynamic severity comparable to the REVEAL.
Side Effects of Drugs in Pulmonary Arterial Hypertension Treatment
One significant restraint is the side effects associated with drugs used to treat pulmonary arterial hypertension. For example, sotatercept, as per the American College of Cardiology, demonstrated an 84% reduction in death and clinical worsening in pulmonary arterial hypertension patients. The STELLAR trial highlighted the efficacy of sotatercept, emphasizing the importance of monitoring potential side effects.
Pulmonary Arterial Hypertension Market Segment Analysis:
Prostacyclin and Prostacyclin Analogues Dominate
The prostacyclin and prostacyclin analogs drug class segment, constituting approximately 39.6%, is dominated by market players during the forecast period. Notably, epoprostenol therapy within this segment significantly improves cardiovascular variables, reduces breathlessness and tiredness, and enhances exercise tolerance in PAH patients.
SGC Simulators - Fastest-Growing Category
SGC simulators are predicted to be the market's fastest-growing category, fostering segment development through the modulation of physiological responses such as vascular smooth muscle, inflammatory suppression, and thrombosis.
Geographical Penetration: North America Leads
North America is poised to dominate the market, holding around 39.1% of the total market share throughout the forecast period. The American Lung Association reports PAH as a rare and progressive disease, contributing to 500-1000 new cases annually in the United States. Efforts by manufacturers, such as the United Therapeutics-supported PAH Initiative, further contribute to market growth by providing tools and information to healthcare practitioners.
Key Global Players in the Pulmonary Arterial Hypertension Market:
Arena Pharmaceuticals
Bayer AG
Bristol-Myers Squibb Company
Gilead Sciences Inc
GlaxoSmithKline Plc
Actelion Pharmaceuticals, Ltd. (Johnson & Johnson)
Merck & Co. Inc
Novartis International AG
Pfizer Inc
United Therapeutics Corporation
Related reports:
serum separation gel market https://www.datamintelligence.com/research-report/serum-separation-gel-market
eczema therapeutics market https://www.datamintelligence.com/research-report/eczema-therapeutics-market
acute migraine drugs market https://www.datamintelligence.com/research-report/acute-migraine-drugs-market
dronabinol market https://www.datamintelligence.com/research-report/dronabinol-market
23 valent pneumococcal polysaccharide vaccine market https://www.datamintelligence.com/research-report/23-valent-pneumococcal-polysaccharide-vaccine-market
anti malarial drugs market https://www.datamintelligence.com/research-report/anti-malarial-drugs-market
Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Arterial Hypertension Market Size, Share, Industry, Forecast and outlook (2024-2031) here
News-ID: 3399244 • Views: …
More Releases from DataM Intelligence 4Market Research
United States Polypropylene Homopolymer Market Set for Strong Growth with Rising …
Market Size and Growth:
The Global Polypropylene Homopolymer Market size reached US$ 91.6 billion in 2024 and is expected to reach US$ 142.72 billion by 2032, growing with a CAGR of 5.7% during the forecast period 2025-2032.
The Polypropylene Homopolymer Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants…
United States Commercial Cleaning Robots Market Surges as Automation Redefines F …
Market Size and Growth:
The US Commercial Cleaning Robots Market size reached US$535.53 million in 2024 and is expected to reach US$2,710.65 million by 2032, growing at a CAGR of 22.7% during the forecast period 2025-2032.
The US Commercial Cleaning Robots Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market…
United States Mental Health Screening Market Surges as Early Diagnosis and Digit …
Market Size and Growth:
The Global Mental Health Screening Market size reached US$ 0.90 billion in 2023, with a rise of US$ 1.00 billion in 2024, and is expected to reach US$ 2.78 billion by 2033, growing at a CAGR of 12.1% during the forecast period 2025-2033.
The Mental Health Screening Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key…
United States Multi Cancer Early Detection Testing Market Set to Revolutionize O …
Market Size and Growth:
The Global Multi Cancer Early Detection Testing Market size reached US$ 1.67 billion in 2023, with a rise of US$ 1.92 billion in 2024, and is expected to reach US$ 7.52 billion by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033.
The Multi Cancer Early Detection Testing Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This…
More Releases for Hypertension
Hypertension Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hypertension Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hypertension Pipeline Report
• DelveInsight's Hypertension…
Hypertension Drugs Market - Breaking the Pressure: Hypertension Drugs Redefining …
Newark, New Castle, USA: The "Hypertension Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypertension Drugs Market: https://www.growthplusreports.com/report/hypertension-drugs-market/8760
This latest report researches the industry structure, sales, revenue,…
Hypertension Management Devices Market: Rise in Prevalence of Resistant Hyperten …
Market Analysis and Insights of Hypertension Management Devices Market
Hypertension Management Devices Market to account USD 9.50 billion and growing at a CAGR of 7.27% by 2032. Although there are still numerous variations available, the major market players are currently developing and testing clinical versions of hypertension treatment devices. Due to the lack of available effective medications, these medical devices are being created with the primary goal of managing cardiovascular illnesses…
Anti-hypertension - Drug Pipeline Landscape, 2022
Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
Renal Hypertension: Diagnosis & Treatment
“Hypertension & Cardiovascular disease after Kidney Transplantation” is one of the workshops to be conducted by Dr. Hossein Tabriziani of Loma Linda University, USA under the session ‘Renal Hypertension’ at the meeting 2nd International Conference on Hypertension & Healthcare which is going to be held at Amsterdam, Netherlands during September 11-13, 2017.
High blood pressure is a leading cause of kidney disease and kidney failure ESRD (end stage renal disease). Hypertension…
